Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 7/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.43 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.39 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14033696 | 0.93 | IRAK4 (0.42) | PDE2APDE10AIRAK4IRAK1KLKB1 | |
| SCHEMBL14033701 | 0.90 | IRAK4 (0.43) | PDE2AIRAK4IRAK1JAK2JAK1 | |
| SCHEMBL14033455 | 0.89 | IRAK4 (0.43) | PDE2APDE10AIRAK4IRAK1JAK2 | |
| SCHEMBL4437012 | 0.88 | KLKB1 (0.42) | PDE2APDE10AIRAK4IRAK1KLKB1 | |
| SCHEMBL4439750 | 0.86 | PDE2A (0.41) | PDE2APDE10AGPR52IRAK4IRAK1 | |
| SCHEMBL14033447 | 0.81 | HSD17B10 (0.47) | PDE2AIRAK4JAK2 | |
| SCHEMBL4437368 | 0.81 | MRGPRX4 (0.42) | PDE2APDE10A | |
| SCHEMBL14033169 | 0.81 | PDE2A (0.42) | PDE2AIRAK4IRAK1 | |
| SCHEMBL4444836 | 0.80 | PDE2A (0.43) | PDE2AGPR52 | |
| SCHEMBL4434781 | 0.78 | NR3C1 (0.47) | PDE2AIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255153-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255153-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-10-16 | — | — | US | disclosed |
| WO-2008116898-A1 | PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE | BIOVITRUM AB (PUBL) (SE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255153-A1 | New compounds | SCD, SCD5, FADS2 | PDE2A 2511/4885PDE10A 3664/4885GPR52 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.